0001209191-19-025793.txt : 20190424 0001209191-19-025793.hdr.sgml : 20190424 20190424181150 ACCESSION NUMBER: 0001209191-19-025793 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190422 FILED AS OF DATE: 20190424 DATE AS OF CHANGE: 20190424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lu Hongbo CENTRAL INDEX KEY: 0001767584 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 19764859 MAIL ADDRESS: STREET 1: C/O AVEDRO, INC., 201 JONES ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-04-22 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001767584 Lu Hongbo C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 225 SAN DIEGO CA 92121 1 0 0 0 Common Stock 2019-04-22 4 C 0 1120730 A 1120730 I By LAV Prime Limited Common Stock 2019-04-22 4 C 0 546820 A 1667550 I By LAV Prime Limited Common Stock 2019-04-22 4 P 0 60000 18.00 A 1727550 I By LAV Prime Limited Stock Option (right to buy) 27.06 2019-04-22 4 A 0 15000 0.00 A 2029-04-21 Common Stock 15000 15000 D Series C Preferred Stock 2019-04-22 4 C 0 4314809 0.00 D Common Stock 1120730 0 I By LAV Prime Limited Series D Preferred Stock 2019-04-22 4 C 0 2105259 0.00 D Common Stock 546820 0 I By LAV Prime Limited Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. The shares were purchased at the Issuer's initial public offering. The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders. /s/ Brian Baker, Attorney-in-Fact 2019-04-24